![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, January 11, 2022 9:49:35 AM
Last week, NRx met with experts from the Israel Institute for Biological Research (IIBR) to review data and research related to the ability of the BriLife vaccine to induce neutralizing antibodies against the Omicron variant. Based on the preliminary findings, NRx is currently designing a phase 2b/3 study of the BriLife vaccine as a booster to protect against COVID-19 variants of concern including the Omicron variant. Patients in the study will be fully vaccinated with mRNA vaccines. It is anticipated that the study will begin in the first quarter of 2021 in Israel and will be expanded in coordination with the health ministries of several countries. The IIBR previously published initial serological findings documenting a neutralizing antibody response against the Delta variant that was comparable to the response against the wild-type SARS-CoV-2 virus.
“We have seen the deadly impact caused by COVID-19 and its increasing number of variants, and we are eager to determine the immunity-building impact the BriLife vaccine may offer on top of that already conferred by baseline mRNA vaccination,” said Prof Jonathan Javitt, MD, MPH, Chairman and CEO of NRx Pharmaceuticals. “We are working closely with the experts at the IIBR to design a study that we hope increases BriLife’s accelerated path to regulatory approval.”
NRx was contacted in late December by representatives of the US Department of Health and Human Services and several European Governments with a request to present Omicron findings.
In further news, the Israel Ministry of Health recently approved a study investigating the NanoPass MicronJet™ intradermal injection system for the BriLife vaccine. The NanoPass system, invented in Israel, uses a patented microneedle system to deliver the vaccine into the skin with minimal discomfort.
This approach is especially promising for the BriLife vaccine because it binds to angiotensin-converting enzyme 2 (ACE2) receptors, which are present in significantly larger quantities in human skin cells than in muscle cells where traditional vaccines are injected. In addition, early data with other vaccines suggests that intradermal delivery of BriLife may result in a more robust immune response at substantially lower vaccine dosing.
As these studies are moving towards initiation, NRx continues technology transfer and scale-up activities in anticipation of commercial scale manufacture by Q4 2022
Good luck and GOD bless,
Recent NRXP News
- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024 • PR Newswire (US) • 06/20/2024 12:30:00 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors • PR Newswire (US) • 06/18/2024 12:30:00 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter • PR Newswire (US) • 06/10/2024 12:30:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: NRX-101 is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipola • PR Newswire (US) • 05/28/2024 12:30:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business Update • PR Newswire (US) • 05/14/2024 08:01:00 PM
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024 • PR Newswire (US) • 05/08/2024 12:30:00 PM
- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024 • PR Newswire (US) • 05/07/2024 08:01:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression • PR Newswire (US) • 05/06/2024 12:30:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression • PR Newswire (US) • 04/30/2024 12:30:00 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement • PR Newswire (US) • 04/18/2024 12:32:00 PM
- NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock • PR Newswire (US) • 04/18/2024 12:30:00 PM
- NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock • PR Newswire (US) • 04/17/2024 08:45:00 PM
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections • PR Newswire (US) • 04/17/2024 12:30:00 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine) • PR Newswire (US) • 04/15/2024 12:30:00 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression • PR Newswire (US) • 04/08/2024 12:30:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • PR Newswire (US) • 04/01/2024 12:28:00 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights • PR Newswire (US) • 03/28/2024 12:03:00 PM
- NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing • PR Newswire (US) • 03/28/2024 12:00:00 PM
- NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024 • PR Newswire (US) • 03/26/2024 08:03:00 PM
- NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK • PR Newswire (US) • 03/25/2024 12:30:00 PM
- NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024 • PR Newswire (US) • 03/21/2024 08:02:00 PM
- NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of Shareholders • PR Newswire (US) • 03/21/2024 05:57:00 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales • PR Newswire (US) • 03/12/2024 11:49:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/11/2024 09:16:06 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine) • PR Newswire (US) • 03/11/2024 12:30:00 PM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM